ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
99.02
+0.52 (0.53%)
At close: Sep 30, 2026, 4:00 PM EDT
99.00
-0.02 (-0.02%)
After-hours: Sep 30, 2026, 4:27 PM EDT
Company Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease.
The company was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme
| Country | France |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 80 |
| CEO | Marc M. de Garidel |
Contact Details
Address: 7-11 Boulevard Haussmann Paris, 75009 France | |
| Phone | 33 1 53 83 09 63 |
| Website | abivax.com |
Stock Details
| Ticker Symbol | ABVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $11.60 |
| CIK Code | 1956827 |
| CUSIP Number | 00370M103 |
| ISIN Number | US00370M1036 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marc M. P. de Garidel M.B.A. | Chief Executive Officer and Director |
| Didier Blondel | EVice President, Chief Financial Officer and Board Secretary |
| Dr. David Zhang Ph.D. | Chief Strategy Officer |
| Dr. Keith M. Fournier Ph.D. | Senior Vice President of Global Regulatory Affairs |
| Michael Nesrallah M.B.A. | Chief Commercial Officer |
| Dr. Maurus de la Rosa Ph.D. | Senior Vice President of Research |
| Ivan Nunez-Pacheco | Global Head of Patient Services |
| Heather Dean | Global Head of Sales, Accounts and Commercial Operations |
| Jeffrey N. Haas | Global Head of Market Access and Pricing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 21, 2026 | F-6EF | Registration of American Depository Receipt shares, immediately effective |
| Sep 21, 2026 | 6-K | Report of foreign issuer |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 13, 2026 | SCHEDULE 13G/A | Filing |
| Jul 6, 2026 | SCHEDULE 13D/A | Filing |
| Jul 2, 2026 | 6-K | Report of foreign issuer |
| Jul 2, 2026 | 424B5 | Filing |
| Jul 1, 2026 | FWP | Free Writing Prospectus |
| Jun 30, 2026 | FWP | Free Writing Prospectus |
| Jun 30, 2026 | 424B5 | Filing |